scholarly journals Plasma Levels of S100B in Preeclampsia and Association With Possible Central Nervous System Effects

2014 ◽  
Vol 27 (8) ◽  
pp. 1105-1111 ◽  
Author(s):  
Lina Bergman ◽  
Tansim Akhter ◽  
Anna-Karin Wikström ◽  
Johan Wikström ◽  
Tord Naessen ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Levels

Monitoring of tricyclic antidepressant plasma levels and clinical response: a review of the literature. Part II

1989 ◽  
Vol 4 (2) ◽  
pp. 81-90 ◽  
Author(s):  
I.R. De Oliveira ◽  
P.A.S. Do Prado-Lima ◽  
B. Samuel-Lajeunesse
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Elderly Patients ◽  
Plasma Levels ◽  
Tricyclic Antidepressant ◽  
Review Of The Literature ◽  
Central Nervous System Toxicity ◽  
Routine Measurement ◽  
System Toxicity

SummaryPart II of this paper contains some general considerations on tricyclic antidepressant (TCA) monitoring. Long-term assessment of TCA plasma levels is advised by the few existent studies, although each of these focusses on different aspects. Cardiovascular and central nervous system toxicity is reviewed as well as pharmacokinetics and the importance of protein binding. Some consideration is also given to their use in elderly patients. The authors conclude that although available data support its usefulness in many situations, routine measurement of TCA levels is not warranted.

scholarly journals Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis

2021 ◽  
Vol 11 (2) ◽  
pp. 238
Author(s):  
Keld-Erik Byg ◽  
Helle H. Nielsen ◽  
Tobias Sejbaek ◽  
Jonna Skov Madsen ◽  
Dorte Aalund Olsen ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Light Chain ◽  
Plasma Levels ◽  
Healthy Controls ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Potential Biomarker ◽  
Fluid Levels

Background: Damage to axonal cells releases neurofilament light chain (NFL) into the cerebrospinal fluid and plasma. The objective of this study was to investigate NFL as a potential biomarker of disease activity in neurosarcoidosis. MRIs were graded according to enhancing lesions at different central nervous system (CNS) sites. Results: In cerebrospinal fluid, levels of NFL were higher in neurosarcoidosis patients (n = 20) median 2304 pg/mL (interquartile range (IQR) 630–19,612) compared to 426 pg/mL (IQR 261-571) in extra-neurologic sarcoidosis patients (n = 20) and 336 pg/mL (IQR 194–402) in healthy controls (n = 11) (p = 0.0002). In plasma, levels of NFL were higher in neurosarcoidosis patients median 28.2 pg/mL (IQR 11.5–49.3) compared to 6.2 pg/mL (IQR 4.3–8.2) in extra-neurologic sarcoidosis patients and 7.1 pg/mL (IQR 6.2–9.0) in healthy controls (p = 0.0001). Levels in both cerebrospinal fluid and plasma were higher in neurosarcoidosis patients with moderate/severe enhancement than patients with mild enhancement on MRI (p = 0.009 and p = 0.005, respectively). To distinguish neurosarcoidosis patients from extra-neurologic patients and healthy controls, a cut-off level of 630 pg/mL in cerebrospinal fluid had 94% specificity and 79% sensitivity, while a cut-off level of 11.4 pg/mL in plasma had 97% specificity and 75% sensitivity. Conclusions: NFL levels in cerebrospinal fluid and plasma are significantly higher in neurosarcoidosis patients compared to extra-neurologic patients and healthy controls, and the levels correlate to the extent of inflammation on MRI.

scholarly journals CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of the central nervous system

2017 ◽  
Vol 25 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Brîndușa Țilea ◽  
Septimiu Voidăzan ◽  
Rodica Bălașa ◽  
Adina Huțanu ◽  
Andrea Fodor
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Infectious Diseases ◽  
Cell Count ◽  
Plasma Levels ◽  
Neurological Diseases ◽  
Protein Levels ◽  
Median Plasma ◽  
The Central Nervous System ◽  
Elisa Technique

Abstract Background: During the acute inflammatory process, the CXCL13 chemokine plays an important role in B cell recruitment within the central nervous system (CNS). Objective: The objective of the study consisted of the evaluation of CXCL13 chemokine cerebral spinal fluid (CSF) and plasma levels in patients with acute infectious and non-infectious neurological diseases correlated with pleocytosis and CSF protein levels. Material and method: This retrospective study was conducted over one year and included 72 patients. Thirty-eight patients (52.8%) suffering from infectious neurological disease, acute viral and bacterial meningitis, meningoencephalitis, and 34 patients (44.2%) diagnosed with non-infectious neurological diseases. CXCL13 chemokine CSF and plasma levels were determined through the ELISA technique with the Human CXCL13/BLC/BCA-1 kit. CSF cell count, glucose and protein levels, along with anti-Borrelia burgdorferi antibodies were monitored using the ELISA technique. Results: CXCL13 chemokine levels in the CSF of patients with acute infectious neurological diseases showed a median value of 23.07 pg/mL, which was significantly higher in comparison with the median value of 11.5 pg/mL of patients with noninfectious neurological diseases (p-0.03). CXCL13 median plasma concentration in patients with infectious neurological diseases was 108.1 pg/mL, in comparison with the second patient category, 50.7 pg/ml (p-0.001). We observed a statistically significant association between CXCL13 concentrations, CSF cell count and proteins. The higher the CXCL13 chemokine level, the more increased the cell count was. Conclusions: CXCL13 levels in the CSF was significantly increased in patients with acute infectious neurological diseases compared with patients with non-infectious diseases. Moreover, CXCL13 chemokine concentration was significantly correlated with the number of cells and proteins in the CSF of patients suffering from neuroinfections.

`Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients'

AIDS ◽  
2001 ◽  
Vol 15 (9) ◽  
pp. 1193-1194 ◽  
Author(s):  
Catia Marzolini ◽  
Amalio Telenti ◽  
Laurent Decosterd ◽  
Jérôme Biollaz ◽  
Thierry Buclin
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Side Effects ◽  
Treatment Failure ◽  
Plasma Levels ◽  
Hiv 1 ◽  
Predict Treatment Failure

Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China

2020 ◽  
Vol 21 (13) ◽  
pp. 945-956
Author(s):  
Rong Chen ◽  
Jun Chen ◽  
Jingna Xun ◽  
Zhiliang Hu ◽  
Qiong Huang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Body Weight ◽  
Plasma Levels ◽  
Dose Group ◽  
Adverse Reactions ◽  
Standard Dose ◽  
Treatment Naïve ◽  
The Central Nervous System ◽  
To Receive

Background: The pharmacogenomics and pharmacokinetics/pharmacodynamics of 400 mg efavirenz have rarely been reported. Materials & methods: A total of 184 treatment-naive HIV-infected patients were randomly assigned (1:1) to receive a lower dose (tenofovir disoproxil 200 mg, efavirenz 400 mg and lamivudine) or a standard dose regimen. Relationships between pharmacogenomics and efavirenz pharmacokinetics/pharmacodynamics were explored at 48 weeks. Results: There was no relationship between pharmacogenomics and adverse reactions of the central nervous system and antiretoviral efficacy. CYP2B6 516G>T, 785A>G, 18492C>T and ABCB1 3435C>T T/C were associated with higher efavirenz plasma levels in the standard but not the lower dose group. No relationship was found between pharmacogenomics and antiretoviral efficacy. Patients who were <60 kg had higher efavirenz concentration compared with those with weight ≥60 kg when using 600 mg efavirenz, this was not observed with 400 mg efavirenz. Conclusion: The effect of pharmacogenomics and body weight on the efavirenz concentration was significant in the 600 mg group but not in the 400 mg group.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

AIDS ◽  
2001 ◽  
Vol 15 (1) ◽  
pp. 71-75 ◽  
Author(s):  
Catia Marzolini ◽  
Amalio Telenti ◽  
Laurent A. Decosterd ◽  
Gilbert Greub ◽  
Jérôme Biollaz ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Side Effects ◽  
Treatment Failure ◽  
Plasma Levels ◽  
Hiv 1 ◽  
Predict Treatment Failure

Regulation of Insulin and Glucose Plasma Levels by Central Nervous System β-Endorphin in Preweanling Rats*

Endocrinology ◽  
1989 ◽  
Vol 124 (5) ◽  
pp. 2153-2158 ◽  
Author(s):  
JORGE V BARTOLOME ◽  
MARIA B BARTOLOME ◽  
EDITH B HARRIS ◽  
JOHN S PAUK ◽  
SAUL M SCHANBERG
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Levels ◽  
Glucose Plasma

Neurotropic enteroviruses co-opt “fair-weather-friend” commensal gut microbiota to drive host infection and central nervous system disturbances

2019 ◽  
Vol 42 ◽  
Author(s):  
Kevin B. Clark
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gut Bacteria ◽  
Infection Cycle ◽  
Fair Weather ◽  
Host Health ◽  
Microbe Interactions ◽  
Animal Hosts ◽  
Host Infection ◽  
Neuropsychiatric Conditions

Abstract Some neurotropic enteroviruses hijack Trojan horse/raft commensal gut bacteria to render devastating biomimicking cryptic attacks on human/animal hosts. Such virus-microbe interactions manipulate hosts’ gut-brain axes with accompanying infection-cycle-optimizing central nervous system (CNS) disturbances, including severe neurodevelopmental, neuromotor, and neuropsychiatric conditions. Co-opted bacteria thus indirectly influence host health, development, behavior, and mind as possible “fair-weather-friend” symbionts, switching from commensal to context-dependent pathogen-like strategies benefiting gut-bacteria fitness.

Sign in / Sign up

Export Citation Format

Share Document